New to peptides? Start with the foundations ->
What it does - plain English
Retatrutide is an experimental once-weekly injection developed by Eli Lilly. It mimics three of your gut and pancreas hormones at the same time: GLP-1 (the one Ozempic mimics, signals fullness), GIP (helps with sugar and fat handling), and glucagon (revs up energy expenditure). The triple action is why early trials show weight loss numbers higher than tirzepatide (the active ingredient in Mounjaro and Zepbound, which hits two of those three targets).
Phase-2 trial readouts in 2023 showed 24%+ average weight loss at 48 weeks. That's larger than Mounjaro/Zepbound's 22.5% at 72 weeks - and it hit that number in less time. Phase-3 trials (the final large-scale round before a drug can apply for FDA approval) are running through 2026-2027.
It is not approved. It is not available. This entry covers what the trial data says and why you should watch it - not how to get it right now.
Status
S-tier pending. The Phase-2 data is the most impressive weight-loss readout published to date for any drug in this class. Phase-3 trials (the TRIUMPH series) are still running. FDA submission is expected 2026-2027 if results hold. It is not yet approved and not yet available outside clinical trials.
Side-effect profile in Phase 2 looked similar to other GLP-1s - nausea, GI (gastrointestinal) distress - but with potentially higher rates given that triple-agonism is a more intense signal to your system. Phase-3 will be the real safety and tolerability test at scale.
If Phase 3 confirms Phase 2, this becomes the new ceiling for what weight-loss medication can do. That's why it's worth knowing now even though it isn't available yet.
Legal status
Retatrutide is not FDA-approved. It is not approved in any country as of May 2026. It is an investigational drug (meaning it's being tested in clinical trials, not available through normal prescribing channels).
What this means in practice:
- Telehealth services don't carry it. The services that prescribe tirzepatide and semaglutide can't legally prescribe something that has no approval yet.
- Compounding pharmacies generally don't have access to the molecule. Eli Lilly hasn't licensed compounding production the way some peptides end up in gray-zone channels.
- Research peptide vendors selling "retatrutide" - that's almost certainly not the trial-grade molecule. Ingredient quality is variable. The risk profile is unknown.
- The right move is to wait. Tirzepatide and semaglutide have years of approved-drug safety records. Retatrutide doesn't yet.
Where to source
There is no legitimate path right now. Telehealth services don't carry it. Compounding pharmacies generally don't have access to the molecule - Lilly hasn't licensed compounding production. Research peptide vendors selling "retatrutide" are almost certainly not selling the trial-grade molecule. What's on the market is gray-zone at best.
The straightforward answer: skip it until commercial launch. Tirzepatide is available, proven, and already produces 22%+ weight loss in trials. That's the move while retatrutide finishes Phase 3.
Subscribe below to get notified when this changes - approval timelines, launch details, and prescribing options will be covered in the weekly dispatch as they happen.
Two studies worth reading
The Phase-2 obesity headline
Jastreboff, A. et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity," NEJM
338 adults with obesity and no diabetes. 24.2% average weight loss at 48 weeks for the highest dose. Beat tirzepatide's headline numbers on a shorter timeline. This is the paper that put retatrutide on everyone's radar.
Phase-2 diabetes readout
Rosenstock, J. et al., "Retatrutide in Patients with Type 2 Diabetes," The Lancet
281 adults with type 2 diabetes (T2D). Strong A1C (average blood sugar over 3 months - the standard diabetes control metric) reduction plus meaningful weight loss. Safety profile similar to tirzepatide. The case for triple-agonism in metabolic disease beyond just obesity.
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.
Last reviewed · 2026·05·04 · Status reviewed weekly